Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00521989 · ClinicalTrials.gov registry record · Phase 2
CRx-102 Osteoarthritis Multicenter Evaluation Trial
A Phase 2 study, sponsored by Zalicus.
- Terminated
- Registry status
- Phase 2
- Development phase
- 279
- Enrollment target
NCT00521989 is a Phase 2 study that was terminated before completion, run by Zalicus. The registered enrollment target is 279 participants.
The verdict
NCT00521989, a Phase 2 study, was terminated before completion, sponsored by Zalicus.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 279 participants
- Enrollment target
Study Summary
CRx-102 is a synergistic combination drug candidate containing the cardiovascular drug dipyridamole and a very low dose of the glucocorticoid prednisolone. CRx-102 is believed to work through a novel mechanism of action in which dipyridamole selectively amplifies the anti-inflammatory and immunomodulatory activities of the glucocorticoid without replicating the dose-dependent adverse effects. CRx-102 has been associated with clinical benefit in proof of concept studies in subjects with hand OA and RA. This is the first study to explore the efficacy of CRx-102 in knee OA. It is considered a dose-finding study and will also compare the potential benefits of CRx-102 treatment to both prednisolone administered alone and to placebo in this indication.
Interventions
- DRUG Placebo
- DRUG Prednisolone
- DRUG CRx-102 (2.7/180)
- DRUG CRx-102 (2.7/360)
- DRUG CRx-102 (2.7/90)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 279 participants |
| Start Date | 2007-08 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00521989
The ClinicalTrials.gov registry entry for NCT00521989 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 279 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Zalicus, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00521989 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00521989 about?
NCT00521989 is a clinical study titled "CRx-102 Osteoarthritis Multicenter Evaluation Trial". CRx-102 is a synergistic combination drug candidate containing the cardiovascular drug dipyridamole and a very low dose of the glucocorticoid prednisolone. CRx-102 is believed to work through a novel mechanism of action in which dipyridamole selectively amplifies the anti-inflammatory and immunomodu...
What is the current status of trial NCT00521989?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 279 participants. The study started on 2007-08. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00521989?
The interventions under investigation include: Placebo (DRUG), Prednisolone (DRUG), CRx-102 (2.7/180) (DRUG), CRx-102 (2.7/360) (DRUG), CRx-102 (2.7/90) (DRUG).
Who is sponsoring clinical trial NCT00521989?
This trial is sponsored by Zalicus, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.